Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Gilbane Building Company Expands Healthcare Market Expertise as Angeles Garcia-Pineda joins Growing Leadership Team as Healthcare Center of Excellence Leader in the West

Leave a comment


Angeles Garcia-Pineda

“She brings an extensive track record of success providing support to healthcare project teams during business acquisition, preconstruction and construction phases,” said Jeff Park, vice president and business leader for Gilbane Northern California.


SAN JOSE, Calif. (PRWEB)

Gilbane Building Company announced that Angeles Garcia-Pineda joined the team as Healthcare Center of Excellence (COE) Leader for the west. As a compassionate leader, Garcia-Pineda brings over 30 years of experience in the construction industry. She will leverage her expertise and relationships to help drive successful client relationships and elevate Gilbane’s focus on bringing value to our clients, trade partners, and the local community.

Garcia-Pineda will combine lessons learned and best practices from her vast experience as a premier builder of healthcare construction projects to expand Gilbane’s existing portfolio. She is passionate about creating projects that have a positive impact on our communities, while developing collaborative and trusting relationships.

“We are thrilled to have Angeles Garcia-Pineda join our leadership team in northern California. She offers notable strengths in working with partners to plan and execute strategies that support the growth and success in the healthcare sector,” said Jeff Park, vice president and business leader for Gilbane Northern California. “She brings an extensive track record of success providing support to healthcare project teams during business acquisition, preconstruction and construction phases.”

“Angeles’ deep healthcare experience brings great value to both owners and project teams,” said Paul J. Choquette III, Regional President, Gilbane Building Company. “Our investment in the West continues to grow as we provide best-in-class solutions to our clients.”

Throughout her career, Garcia-Pineda has been a champion for Lean culture and processes. She is an advocate for high standards and works closely with clients, owners, designers, architects, engineers, and authorities to ensure the successful completion of a project. She has also served as a mentor in a protégé program, providing pro bono construction management services and is proud to help facilitate projects for her community. She is a two-time recipient of the Northern California Real Estate Woman of Influence award and passionate about women in leadership roles of construction management.

“I’m thankful for the opportunity to be part of one of the leading and largest family-owned construction companies building impactful projects in our communities,” said Garcia-Pineda. “It is an honor to be part of Gilbane’s next chapter in the west as we continue to grow, forge new partnerships and expand our client base.”

Garcia-Pineda has a Bachelor of Architecture (BArch) from Tijuana Institute of Technology.

About Gilbane Building Company

Gilbane provides a full slate of construction and facilities-related services – from preconstruction planning and integrated consulting capabilities to comprehensive construction management, general contracting, design-build, and facility management services – for clients across various markets. Founded in 1870 and still a privately held, family-owned company, Gilbane has more than 45 office locations worldwide. With offices in Sacramento and San Jose, Gilbane has delivered innovative construction solutions across northern California since 1995. For more information, visit http://www.gilbaneco.com.

Share article on social media or email:

Health

Schlafender Hase® releases TVT version 11.1 with new functionalities for an e-labelling environment

Leave a comment


“We are harmonizing the process of proofreading in paper, paperless, or hybrid systems, and that simplifies the workflow in order to deliver accurate, up-to-date information, now and in the future, to patients and healthcare professionals” explains Mike Baird, Director of Product Development.


FRANKFURT, Germany (PRWEB)

Schlafender Hase® announced today the release of TVT 11.1, the latest version of its industry-leading proofreading software. Functionalities integrated into TVT 11.1 simplify text verification and workflows in an electronic labelling (e-labelling) environment, in which consumers and patients typically use mobile scanning and other technologies to access product information online, often via a smartphone app.

Among its new features, TVT 11.1 includes a functionality that allows the user to compare an online version of a document, such as a Product Information Leaflet (PIL), with an approved master document by simply inserting a website URL. In addition, TVT 11.1 can also compare files in their native HTML and XML formats.

This new version follows the November 2022 release of TVT 11 and still includes powerful technology that allow users to quickly and easily upload and process documents of virtually any size. TVT 11.1 can also be augmented by optional add-on modules TVT Spelling® and TVT Artwork®. To verify readability of 1D and 2D barcodes (e.g. QR codes), TVT Barcode® can also be included.

“One of our tenets at Schlafender Hase is that our software should verify content regardless of form or format,” explains Frank Hessler, founding CEO of Schlafender Hase. “For our customers and users in Life Sciences – and that includes Regulatory Bodies themselves – the primary goal of maintaining consistency and regulatory compliance across different media, physical and online, can be easily achieved with TVT 11.1.”

“Mobile scanning and related technologies are rapidly changing how essential information is sourced and delivered,” explains Mike Baird, Director of Product Development of Schlafender Hase, “and this change is happening at a differing pace throughout the world. With TVT 11.1, we are harmonizing the process of proofreading in paper, paperless, or hybrid systems, and ultimately that simplifies the workflow in order to deliver accurate, up-to-date information, now and in the future, to patients and healthcare professionals.”

About Schlafender Hase

Schlafender Hase serves regulated industries across the globe. Clients include the world’s leading pharmaceutical and medical device companies, as well as healthcare regulatory bodies. The continued success of Schlafender Hase is based on delivering quality products and a strong understanding of customer pain points. Our easy-to-use products reduce proofreading workloads, assure the quality of printed and online materials and mitigate the risk of costly errors.

Founded in 2001, Schlafender Hase GmbH is headquartered in Frankfurt am Main, Germany, with a subsidiary in the US. More at http://www.schlafenderhase.com

Share article on social media or email:

Health

Icahn School of Medicine at Mount Sinai Dean and Researcher Receives Prestigious Award in Psychopharmacology

Leave a comment


“Progress in the field of pharmacological treatments for major psychiatric disorders such as schizophrenia, bipolar disorders, multiple anxiety disorder, and attention deficit disorder has been too slow compared to other serious diseases such as cancer and heart disease.” – Dr. Charney


NEW YORK (PRWEB)

Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP). The award was presented to Dr. Charney during the ASCP’s annual meeting on Wednesday, May 31.

The award is presented annually to an individual who has made an outstanding contribution to the field of clinical psychopharmacology. It is named in honor of Dr. Klein, who brought a rational and pragmatic approach to modern clinical psychopharmacology and the concepts behind major mood disorders. His work was fundamental not only in shaping the modern understanding of clinical depression, but also in defining the nature of clinical psychopharmacology trials.

A world-renowned expert in neurobiology and treatment of mood and anxiety disorders, Dr. Charney has made significant contributions to the understanding of and therapeutic approaches to human anxiety, fear, depression, and resilience. His work demonstrating that ketamine is a rapidly acting antidepressant has been recognized as one of the most exciting advances in antidepressant therapy in more than half a century. Most notably, Dr. Charney is named as a co-inventor on a patent for the use of ketamine as a therapeutic approach for patients with treatment-resistant depression. The treatment, which received the overwhelming support of a Food and Drug Administration panel in February 2019, has the potential to be life-changing for millions of patients with an often-devastating disease.

Elected to the Institute of Medicine of the National Academy of Sciences in 2000, Dr. Charney has been honored with every major award in his field for his research. He has also written or co-authored more than 700 publications, including groundbreaking scientific papers, chapters, and several books including Resilience: The Science of Mastering Life’s Greatest Challenges, which will be available in its third edition this September.

“Progress in the field of pharmacological treatments for major psychiatric disorders such as schizophrenia, bipolar disorders, multiple anxiety disorder, and attention deficit disorder has been too slow compared to other serious diseases such as cancer and heart disease,” said Dr. Charney. “Dr. Klein recognized that therapeutic discovery for mental illness needs a paradigm change, and he became an inspiration for me and other researchers through his groundbreaking work. It is an honor to receive this award and to continue his legacy by using new data from molecular biology, genetics, neural circuitry, and other scientific fields to identify new and novel therapies for serious mental illness.”

About the Icahn School of Medicine at Mount Sinai:

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

——————————————————-

  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Share article on social media or email:

Health

Genomenon Acquires Boston Genetics to Accelerate Curation of Human Genome

Leave a comment


Genomenon and Boston Genetics

“This acquisition builds on our success and puts us in the lead in the race to curate the entire human genome – bringing unprecedented actionable genomic insights for clinical diagnostic, newborn sequencing and drug development programs.” – Mike Klein, CEO


ANN ARBOR, Mich. and CAMBRIDGE, Mass. (PRWEB)

Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge and tech-enabled scientific expertise with Boston Genetics’ substantial team of genetic scientists, Genomenon is now in the lead position to be the first company to curate the entire human genome. The insights through this curation, starting with the clinical exome, will be invaluable in Genomenon’s mission to save and improve lives by making genomic information actionable.

The expanded team size and genomic expertise immediately empowers Genomenon to offer even greater support to its clinical diagnostic and pharmaceutical clients as it helps both groups understand the genomic drivers of genetic disease and oncology. In addition, the acquisition creates a genomics data service arm for Genomenon, allowing the company to provide cost-effective variant curation team extensions for genetic testing labs to speed up their turnaround times.

Genomenon CEO Mike Klein explained, “Genomenon has always been unique in our approach of combining genetic expertise with our AI-driven genomics engine, Mastermind, which has 100 times more genomic evidence and 50 times more variants than any other resource.” He continued, “We have partnered with Boston Genetics for more than three years now and have been consistently impressed with the quality of the team’s expertise and work. This acquisition builds on our success and puts us in the lead in the race to curate the entire human genome – bringing unprecedented actionable genomic insights for clinical diagnostic, newborn sequencing and drug development programs.”

Boston Genetics Co-Founder and CEO Arslan Berbic will be joining the Genomenon team as its Vice President of Business Development, Services Platform. He commented, “I am proud of the company my team and I have built with Boston Genetics and am thrilled to now have it as part of Genomenon to further power the company’s mission to curate the genome. As a member of the Genomenon team, I am excited as we work to expand our curation and variant interpretation services to our customer base by leveraging Genomenon’s AI curation engine with expert review by the Boston Genetics team.”

The acquisition, which is effective immediately, adds more than 75 highly trained genetic scientists to the Genomenon team, doubling the size of the company. Boston Genetics’ current customers include a number of top genetic testing labs across the US which will now have access to Genomenon’s AI-driven curation engine and services platform.

About Genomenon

Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

For more information, visit Genomenon.com.

About Boston Genetics:

Boston Genetics was founded in 2019 and is headquartered in Cambridge, MA with offices also across Bosnia. Its genomic interpretation services specialize in germline & somatic curation to ACMG/AMP clinical guidelines. Curators are experienced in working with bioinformatics, ClinGen and medical teams and are designed to augment customers’ variant curation teams.

For more information, visit Bostongen.com.

Share article on social media or email:

Health

The First & Only Diagnostic Test for Periodontal Disease in Pets…

Leave a comment


EPiQ Animal Health Announces the Distribution of OraStripdx, the Only Rapid Diagnostic Test for Periodontal Disease. Partnership Increases Access to Better Preventive Oral Health Care for Millions of…

(PRWeb June 26, 2023)

Read the full story at https://www.prweb.com/releases/the_first_only_diagnostic_test_for_periodontal_disease_in_pets_announces_distribution_partnership/prweb19411636.htm

Health

American Canadian School of Medicine Achieves Accreditation Exceptional Facilities, Innovative Curriculum and An Esteemed Faculty Distinguishes the New Medical School

Leave a comment


IAAR Accreditors meet with ACSOM Administration in Dominica

In an industry where securing WFME accreditors can be a challenge, American Canadian School of Medicine has achieved the remarkable feat of securing accreditation before the start of our inaugural class. This is a truly outstanding achievement


PORTSMOUTH, Dominica (PRWEB)

The American Canadian School of Medicine (ACSOM) is delighted to announce that it will begin its inaugural class with accreditation by the Independent Agency on Accreditation and Rating (IAAR), which is recognized by the World Federation of Medical Education (WFME). Achieving IAAR accreditation included an extensive inspection of the campus and teaching facilities, intensive review of the curriculum and a series of interviews with faculty and school leadership.

“In an industry where securing WFME accreditors can be a challenge, American Canadian School of Medicine has achieved the remarkable feat of securing accreditation before the start of our inaugural class. This is a truly outstanding achievement,” says Ramin Ahmadi, MD, MPH, founding dean of ACSOM and former associate clinical faculty at Yale School of Medicine.

The state-of-the-art teaching facilities were a significant factor in the school receiving approval by IAAR. ACSOM has classrooms and laboratories outfitted in modern technology, including simulated patient care environments that offer realistic medical experiences to support student learning and development. Traditional amenities are also offered such as a campus library, computer labs, and student lounges.

With the successful completion of the accreditation process, ACSOM is poised to launch its four-year curriculum in August. The program will start with a two-year basic sciences program in Dominica followed by two years of clinical rotations at teaching hospitals located in the United States and Canada.

“American Canadian School of Medicine is truly forward-thinking in its approach to medical education. From the beginning, students are engaged in a team-based, problem-solving learning environment where clinical medicine is intentionally integrated throughout the basic sciences curriculum,” says Ahmadi emphasizing the school’s commitment to ensuring that students are prepared for clinical medicine.

The strength of ASCOM’s curriculum is largely attributed to a dedicated team of full-time physician faculty who bring their training and experience from revered medical schools such as Yale University

School of Medicine, Weil Cornell Medical College, New York University, Penn State University’s Milton S. Hersey Medical Center, SUNY Downstate Medical Center and Western University in Canada.

With enrollment deadlines fast approaching, ACSOM is prepared to receive another surge in applicants in the upcoming weeks.

American Canadian School of Medicine

The American Canadian School of Medicine (ACSOM) is the first nonprofit international medical school in the Caribbean, with its campus based in Dominica. ACSOM offers a comprehensive medical education program with a primary focus on preparing students for residency training in North America. ACSOM is accredited by the International Agency for Accreditation and Rating (IAAR), which is recognized by the World Federation of Medical Education (WFME).

For more information about the American Canadian School of Medicine, please visit http://www.acsom.edu.dm

Share article on social media or email:

Health

MedStar Health Announces Emily Briton as Sixth President of MedStar Montgomery Medical Center

Leave a comment


We have important work ahead of us, bringing high-quality personalized care to our community and continuing our mission to be the trusted leader in caring for people and advancing health.


OLNEY, Md. (PRWEB)

MedStar Health announced that Emily Briton will be the newest president of MedStar Montgomery Medical Center and senior vice president, MedStar Health as of July 1, 2023. Briton previously held several leadership roles within the MedStar Health system, most recently serving as chief operating officer and senior vice president at MedStar Washington Hospital Center in Washington D.C.

“It is a tremendous honor to be joining MedStar Montgomery Medical Center in this exciting role,” said Briton, a longtime resident of Montgomery County. “We have important work ahead of us, bringing high-quality personalized care to our community and continuing our mission to be the trusted leader in caring for people and advancing health.”

The announcement follows news of the appointment of President Thomas J. Senker, FACHE, as the next president of MedStar Union Memorial Hospital and MedStar Good Samaritan Hospital, also effective July 1, 2023.

“I want to thank T.J. for his leadership, and I am eager to continue this great hospital’s long-standing mission,” said Briton.

“I am thrilled for Emily to step into the role as President of MedStar Montgomery Medical Center,” said Senker. “Emily is an immensely talented leader, and I have great confidence that she will continue to move the organization forward for the benefit of our community.”

Senker’s tenure has yielded numerous accomplishments for the medical center. Chief among these are groundbreaking facility openings and service enhancements, including the Center for Successful Aging and Women’s Health and Outpatient Radiology at Olney, in 2019 and 2021 respectively. Additionally, he oversaw great philanthropic progress through community partnerships, including a $2M gift from the Women’s Board at MedStar Montgomery Medical Center, a $1.8M estate donation from Robert (Bobby) E. Lee Smith Jr., and a $250K gift from Sandy Spring Bank.

Briton enters the role as an accomplished and seasoned leader in her own right. In the Greater Washington community, her honors include the Jewish Federation of Greater Washington’s Capital Chai Award, membership in Leadership Greater Washington Class of 2023 and America’s Essential Hospitals 2023 Women’s Leadership Academy.

Outside of her professional role, Briton guest lectures at the George Washington University Milton School of Public Health. She holds a Master of Health Administration from George Washington University and Bachelor of Science in kinesiology from The University of Texas. In addition, she serves as a member of the American College of Healthcare Executives.

For information about MedStar Montgomery, visit: https://www.medstarhealth.org/locations/medstar-montgomery-medical-center.

Share article on social media or email:

Health

Dr. Erez Dayan with Core Aesthetics Introduces a Cutting-Edge Liposuction Training Course in Reno Using the Latest Radio Frequency Assisted Techniques

Leave a comment


News Image

“I am confident that participants of this comprehensive training course will be equipped with the skills necessary to provide exceptional liposuction treatment while ensuring patient satisfaction and safety,” says Dr. Erez Dayan.


BEVERLY HILLS, Calif. (PRWEB)

Dr. Erez Dayan, a distinguished authority in the field of aesthetic medicine, is delighted to introduce the Liposuction under Local Anesthesia 101 course, which promises to deliver an unparalleled training experience for medical professionals seeking to enhance their skills and knowledge in the field of liposuction. Taking place on the scheduled dates as outlined on the official website, (https://www.coreaesthetics.com/liposuction-under-local-anesthesia-101/), this course offers an exceptional opportunity for practitioners to gain valuable insights and practical expertise in the most advanced liposuction techniques available today.

Course Highlights:

Unparalleled Education: Dr. Dayan’s liposuction training course encompasses the latest developments in radio frequency-assisted liposuction techniques. Participants will be immersed in a comprehensive curriculum that covers key topics, including patient assessment, pre-operative planning, treatment protocols, safety measures, and post-operative care.

Hands-on Training: Attendees will have the unique opportunity to apply their newfound knowledge in practical exercises under the guidance of Dr. Dayan. Through interactive workshops, participants will gain proficiency in using state-of-the-art liposuction equipment and technology.

Expert Guidance: Dr. Erez Dayan, a respected authority in the field, will share his wealth of knowledge and experience gained from years of successful liposuction procedures. Attendees will benefit from his invaluable insights, practical tips, and personalized feedback, enabling them to refine their techniques and provide exceptional patient care.

Networking Opportunities: The course fosters an environment conducive to networking, enabling participants to connect with like-minded professionals from various medical backgrounds. Attendees will have the chance to exchange ideas, discuss challenges, and forge collaborations, enriching their overall learning experience.

“I am confident that participants of this comprehensive training course will be equipped with the skills necessary to provide exceptional liposuction treatment while ensuring patient satisfaction and safety,” says Dr. Erez Dayan.

To secure a place in the upcoming Liposuction under Local Anesthesia 101 course, interested individuals are encouraged to visit the official website (https://www.coreaesthetics.com/liposuction-under-local-anesthesia-101/) and complete the registration process. Limited seats are available, so early booking is recommended.

About Dr. Erez Dayan and Core Aesthetics:

Dr. Erez Dayan completed his plastic & reconstructive surgery training through the Harvard Plastic Surgery program. During his training, Dr. Dayan gained extensive experience in both reconstructive and aesthetic plastic surgery. He is trained in a comprehensive range of plastic surgery procedures with a particular interest in facial aesthetic surgery, rhinoplasty, breast augmentation and non-invasive treatments. He has worked closely with the world’s leading experts in the areas of breast reconstruction, complex microvascular reconstruction, face transplantation and aesthetic surgery. As a passionate educator, Dr. Dayan strives to share his knowledge and empower aspiring professionals in the field of aesthetic medicine.

Core Aesthetics Academy was established to meet the demands of the rapid influx of diverse providers in the aesthetic market that need provider training and education to ensure quality and safety standards are maintained. The purpose of Core Aesthetic Academy is to provide the practitioner with a clear and systematic approach to the aesthetic patient at all levels of expertise – from novice to advanced practitioners. For additional information, please visit http://www.coreaesthetics.com.

Share article on social media or email:

Health

GlobalMed Technologies Launches Topical Skincare Line Created to Optimize LED Light Therapy Results Before, During, and After Treatments

Leave a comment


News Image

“What I love about this new skincare line is how versatile it is. Not only does it enhance the LED light effects, but it can also be used as a stand-alone skincare line and offers outstanding skin benefits,” says Dr. Hany Abi Ghosn


NAPA, Calif. (PRWEB)

GlobalMed Technologies (GMT) announced today that it has launched a line of topical skincare products, developed specifically to further optimize the brand’s clinically proven LED light therapy treatments, Omnilux Contour™ Face and Omnilux Men™.

“We are proud to be the world leader in medical-grade LED light therapy devices and the launch of our topical skincare line is just another step in continuing to innovate for our customers and professional partners,” says Quinten Stanier, President of Omnilux. The trio, formulated by world-renowned aesthetics doctor,

Dr. Hany Abi Ghosn, has been created to optimize LED light therapy results before, during, and after treatments.“

What I love about this new skincare line is how versatile it is. Not only does it enhance the LED light effects, but it can also be used as a stand-alone skincare line and offers outstanding skin benefits,” says Dr. Hany Abi Ghosn. “The ingredients have been thoroughly selected following a lot of research to get the best synergy with the LED light.

”The products in the new line include an Enzyme Powder Cleanser (pre-LED treatment), a soothing facial cleaner enriched with green tea and rice powder that renews, brightens, and improves skin’s texture through ultra-gentle exfoliation, a Hyaluronic Acid Serum (during-LED treatment), a serum that amplifies LED light therapy treatment with an optimal combination of hyaluronic acid and niacinamide to help plump skin, reduce redness and diminish signs of fatigue and inflammation, and a Peptide Concentrate (post-LED treatment), a multi-peptide concentrate of Matrixyl + Argireline that helps reduce the appearance of fine lines and fatigue. With over 40 clinical studies proving the effectiveness of its technology, Omnilux is the brand of LED phototherapy systems most recommended and used by dermatologists worldwide for in-office treatments. Now, the company is further optimizing the results consumers can expect from their products with topical skincare to accompany the treatments. For more information on the company and its products, visit http://www.omniluxled.com.

About Omnilux

Omnilux is the most tested and trusted brand of LED phototherapy systems on the market today and has been the gold standard around the world for medical and aesthetic applications since 2003. With over 40 published peer-reviewed clinical papers and 20 years of research, Omnilux has pioneered the use of their best-in-class LED technology in convenient, home-use devices. Their Contour collection was first released in November 2020 and uses optimized doses of red and near-infrared light to supercharge the body’s own natural cellular healing response and reverse the visible signs of aging. In September of 2021, Omnilux launched CLEAR, the first and only flexible home-use, FDA-cleared red and blue LED light therapy mask proven to significantly reduce or eliminate acne. In November of 2022, Omnilux continued to innovate with the result of Omnilux Men, the first and only LED mask calibrated with the deepest penetrating wavelength of near-infrared light to meet men’s specific skin needs.

About GlobalMed Technologies

GlobalMed Technologies (GMT) is a leading medical technology company based in the San Francisco Bay Area. Specializing in light-based devices used in various clinical and cosmetic applications, throughout its almost 25-year history GMT has manufactured or distributed some of the most recognizable brands in the industry, including: Omnilux Medical™, Strata XTRAC™, CoolTouch™, VASER™, BTL™, and Radiancy™

###

Press Contact

Jeneration PR for Omnilux

Sarah Blackledge

sarah@jenerationpr.com

Share article on social media or email:

Health

Wearable Pump Innovator Freemie Sues Elvie Alleging Patent Infringement

Leave a comment


Dao Health, the American company first to successfully commercialize wearable and concealable breast pumps, has filed a lawsuit in US federal court alleging willful patent infringement against Chiaro Technology Limited, the British-based company behind the “Elvie” brand of breast pumps.


EL DORADO HILLS, Calif. (PRWEB)

Dao Health, the American company first to successfully commercialize wearable and concealable breast pumps, has filed a lawsuit in US federal court alleging willful patent infringement against Chiaro Technology Limited, the British-based company behind the “Elvie” brand of breast pumps. Dao Health, which markets its products under the Freemie® brand, first filed patents for its revolutionary devices in 2004 and launched its first product in 2009. After the company launched a full line of wearable breast milk pumps in 2013, it quickly became available through health insurance channels. Freemie® is still the only wearable breast pump widely available and 100% covered for US moms under most health insurance plans.

Inspired by personal challenges arising from the premature birth of the founders’ twins, Dao Health evolved from a small, self-financed startup, into a trailblazing pioneer whose founding idea is changing the culture of modern motherhood. Prior to the introduction of Freemie® pumping systems, women were relegated to private rooms, closets, or even airport bathrooms to pump milk for their babies because existing breast pumps required users to undress. After struggling for its first few years while figuring out how to navigate around the roadblocks to women pumping in public, Freemie wearable pump systems finally broke through the traditional cultural barriers. Word spread rapidly thereafter through social media, and today the popularity of wearable designs continues to grow.

Freemie won the “Best of Baby Tech” award in January, 2016 at the Consumer Electronics Show in Las Vegas, a leading consumer products trade show that garners worldwide press, as well as a coveted Edison Innovation Award Gold Medal for Health and Wellness, presented in New York City in 2017, with many titans of industry in attendance. Chiaro did not launch its first Elvie pump until late 2018.Virtually every wearable pump design now available is modeled on the form factor pioneered by Freemie®. Wearables have become a viable alternative, as countless moms in reviews say wearable pumps are indispensable in their busy lives to enable continued breastfeeding, which is exclusively recommended for the first six months of a baby’s life.

Dao Health is represented by attorneys Meng Xi, Shawn Blackburn and Bryce Barcelo of Susman Godfrey, a Houston-based law firm that is widely regarded in legal circles as one of America’s leading litigation firms, together with Andrea Fair of Longview, Texas-based Ward, Smith & Hill, also well known for high-stakes litigation involving intellectual property. The case is Dao Health v. Chiaro Technology Limited, 2:23-CV-00289, in the United States District Court for the Eastern District of Texas, Marshall Division.

ABOUT DAO HEALTH

UCSF and Stanford-trained emergency physician Dr. Stella Dao, Freemie’s co-inventor, and her husband, Dan Garbez, conceived their redesign of the traditional breast pump following the premature birth of the couple’s twins in 2004. Dr. Dao realized that the demands of her job as an emergency physician presented serious impediments to her ability to breastfeed her twins with the traditional breast pumps available at that time. Dr. Dao knew that for her premature twins, breast milk was critical to their well-being. She also knew that millions of other new moms have urgent and demanding responsibilities, whether at work or at home, that made pumping challenging or impossible. Something had to change.

Most breastfeeding advocates and health professionals tried to address these problems for new moms by focusing on changing policies, such as promoting more maternity leave, or requiring more employers to provide extra breaks and private rooms dedicated for pumping. But Dr. Dao and Mr. Garbez saw a much simpler and quicker solution, by providing a tool for the job that was designed for the actual environment in which it needed to be used. A simple, effective, concealable, wearable pump would give women direct control over how they feed their infants, regardless of their lifestyle, employers, or other prior impediments.

Dr. Dao’s approach was radical and revolutionary. In 2019, Dr. Dao was invited by the UCSF School of Medicine, her alma mater and one of the world’s premiere health care research institutions, to receive the school’s “Audacious Alumni Award”. Presenting the award to Dr. Dao, UCSF Chancellor Dr. Sam Hawgood, a neonatologist, said, “Dr. Dao’s work stands out for its audacity in challenging an entrenched system that forced a new mother to make the choice either to give up her employment, or to give up on providing the best for the child’s health and wellbeing.”

Dao Health has recently begun licensing its patents in an effort to encourage more innovation to benefit maternal and infant health. Notably, the first licensee of the company’s foundational patents is Medela, the Swiss-based global leader of the industry that has done more than any other company to create the market for breast pumps, and has also sponsored or performed some of the most important basic research into the science of human milk that benefits maternal and infant health globally.

Share article on social media or email: